Search for drugs:
Typing the drug name to query
DROXIDOPA
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- No prolongation of the QTc interval was observed with NORTHERA at single oral doses up to 2,000 mg, as shown in a dedicated thorough QT study.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
3
24089
Other ADRs
41681
38339906
Odds Ratio = 0.115
Drug Property Information
ATC Code(s):
- C01CA27 - droxidopa
- C01CA2 -
- C01CA - Adrenergic and dopaminergic agents
- C01C - CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
- C01 - CARDIAC THERAPY
- C - CARDIOVASCULAR SYSTEM
Active Ingredient:DROXIDOPA
Active Ingredient UNII:J7A92W69L7
Drugbank ID:DB06262
PubChem Compound:92974
CTD ID:D015103
PharmGKB:PA164748386
CAS Number:23651-95-8
Dosage Form(s):capsule
Route(s) Of Administrator:oral
Daily Dose:
- 1000.0 mg/day C01CA27
Chemical Structure: 
SMILE Code:
N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.